mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE) introduction Hepatocellular carcinoma (HCC) accounts for the most common primary malignancy of the liver. It is the sixth most common malignancy worldwide [1] and the third most common cause of cancer-related death globally behind only lung and stomach cancers [2] . In the United States, its incidence has increased three-fold from 1975 to 2005 [3] . Because most patients present with intermediate or advanced disease, curative surgical resection is an option for <20% patients [4] . Non-operative patients may be considered for systemic and locoregional therapies (LRTs). LRTs have shown improved survival in patients with unresectable HCC by inducing necrosis and delaying progression of the disease [5] [6] [7] [8] [9] [10] [11] [12] .
The radiographic tumor response is essential in cancer research and to assess treatment and survival. Conventionally, the radiographic response rate is measured in terms of tumor shrinkage using world health organization (WHO) and standard response evaluation criteria in solid tumors (RECISTs), which are based on the sum of the greatest dimensional measurement of target lesions [13] [14] [15] [16] . However, in the case of HCC, recent studies have shown a poor correlation between the clinical benefit provided by new agents such as sorafenib or by LRTs and conventional methods of assessment [17] [18] [19] . In a patient with HCC, the main objective of all effective LRTs is to induce necrosis of the tumor, regardless of the shrinkage of the lesion. Therefore, in 2000, a panel of experts on HCC of the European Association for the Study of Liver (EASL) amended the response criteria to take into account tumor necrosis induced by treatment [20] . In 2008, the American Association for the Study of Liver Disease (AASLD) developed a set of guidelines which included a formal modification of the response assessment based on the RECIST criteria and aimed to translate into the concept of viable tumor (tumoral tissue showing arterial uptake in the arterial phase of contrast-enhanced imaging techniques), which are referred to as modified RECIST (mRECIST) criteria [21, 22] .
The objectives of this study were to compare the concordance/agreement of tumor response evaluated by WHO, RECIST, EASL, and mRECIST guidelines on post-treatment magnetic resonance imaging (MRI) scan at early time point, and to correlate them with survival after doxorubicin drugeluting beads transarterial chemoembolization (DEB TACE) in patients with unresectable HCC.
materials and methods
This is a single institutional correlative retrospective analysis of a prospective study with patient's consent. (clinical trial number: NCT0153999, registered on www.clinicaltrials.gov website), approved by the local Institutional Review Board (IRB), and is Health Insurance Portability and Accountability Act (HIPAA) compliant.
patient cohort
We included the patients who had contrast-enhanced dynamic (triphasic) abdominal MRI studies, carried out at our institution before and after DEB TACE of first cycle of DEB TACE therapies. Here, first cycle of DEB TACE therapies means initial consecutive DEB TACE treatments carried out every 4 weeks to treat initially presented HCC tumors. The first cycle includes maximum up to four DEB TACE treatments. The study period was 5 years, from 1 May 2006 to 30 April 2011. There were 120 patients, who had contrast-enhanced dynamic (triphasic) abdominal MRI studies, carried out at our institution before and after DEB TACE of first cycle, and were considered eligible and included in the study. We included only MRI studies due to its known high sensitivity and specificity for detecting HCC compared with the computed tomography (CT) scan. The records of these HCC patients were studied in detail. The patients, who had curative surgical treatments or who did not have either pre-and/or post-treatment MRI study at our institution, were excluded from the study. The baseline staging was carried out by different criteria. The AASLD-Journal of the National Cancer Institute (JNCI) guidelines [23] were used to diagnose HCC. For lesions between 1 and 2 cm, two different studies were used to detect the typical pattern and for nodules >2 cm in diameter, only one study was used. Lesions with inconclusive features on imaging were biopsied for pathologic confirmation (n = 3).
DEB TACE procedure and follow-up
The transcatheter therapy was carried out via a femoral artery approach. The arteries directly supplying the tumor were catheterized super selectively and were treated with DEB TACE using 300-500 and 500-700 μm Patients with large tumors of >5 cm or multifocal disease were brought back in 4 weeks for a repeat session. The remainder of the patients were followed up in the clinic in 4 weeks with liver function tests and an MRI of the liver. In patients with progression of disease (PD), adjuvant systemic chemotherapy is also considered.
magnetic resonance imaging
All MRI studies were carried out on 1.5-T (GE Medical Systems, Milwaukee, WI) and 1.5/3-T MRI scanners (Siemens Health-Care, Erlangen, Germany). Our routine liver protocol consisted of a combination of single-shot T 2 -weighted (T2W) images and dynamic, contrast-enhanced sequences extending from the lung bases through the kidneys. The T 1 -weighted (T1W) gradient resonance echo images were obtained in the pre-contrast phase and subsequently in the arterial, venous, and delayed phases. The time delay between the contrast bolus trigger point and acquisition initiation was 8 s. Venous phase imaging was initiated at 70 s after the bolus trigger point, providing adequate time for patient recovery and a second breath hold. The delayed phase images were acquired at 180 s after the bolus trigger point.
methodology of radiologic response assessment
The radiologic treatment response was assessed using RECIST 1.1, WHO, EASL, and mRECIST criteria [13] [14] [15] [16] [20] [21] [22] on gadolinium-enhanced dynamic MRI scans. The details of these criteria are discussed in Table 1 . EASL and mRECIST criteria define a viable tumor as an enhancing tumor on the arterial phase of T 1 post-contrast images.
The radiologic response was divided into the target lesion response and the overall response. The target responses for RECIST 1.1 and mRECIST are defined as those that assess up to two measurable lesions in the liver, whereas, for WHO and EASL, all hepatic lesions are considered according to WHO and EASL response guidelines (Table 1) . Target response only included changes of lesions treated by DEB TACE. The overall responses took into consideration of target and non-target lesions. For example, the development of new HCC lesion(s), new portal vein thrombosis, or new extrahepatic metastatic lesion was considered as PD for overall response, but not for target response. For each patient, the radiologic overall and target treatment responses were measured according to the four different response guidelines (Table 1 ). The patients with complete response (CR) or partial response (PR) were considered as responders and those with stable disease (SD) or PD were categorized as non-responders.
Radiographic interpretation was provided by two radiologists with 11 and 1.5 years of experience interpreting imaging response on pre-treatment and 6 weeks post-treatment MR studies utilizing high-resolution PACS workstations. Review sessions were carried out independently and on different days. In the case of a discrepancy in response assessment, the images were reviewed together by the radiologists, and a consensus decision was reached.
statistical analysis
The kappa statistics were used to determine inter-method agreement. The k coefficient of 0.75-0.80 represents an excellent inter-method agreement [24, 25] . The overall median survival since first DEB TACE treatment was estimated by Kaplan-Meier method and compared between different categories with the log-rank test. The Cox proportional model was employed to estimate the hazard ratio (HR) of each category compared with PD among each method, respectively. Both methods were used to explore differences in target and overall survival between the responders and non-responders according to WHO, RECIST 1.1, EASL, and mRECIST criteria. A P-value of <0.05 was considered significant. The chi-squared (χ 2 ) test was used for comparing categorical variables. SPSS software, version 19.0 (IBM, Somers, NY) was used to perform the statistical analyses.
results baseline characteristic Table 2 summarizes the detailed baseline characteristics of the 120 patients. Overall, there were 95 men (79.2%) and 25 inter-method agreement response rate and association with survival
The median period between the baseline pre-treatment MRI scans and DEB TACE therapies was 30 days (range 0-125).
The median period between the DEB TACE therapies and post-treatment assessment MRI scans was 33.5 days (range 0-113). In 61.7% (n = 74) of patients, MRI scans (to assess treatment response) were carried out after first DEB TACE with a median period of 33.50 days. In 33.3% (n = 40) of patients, MRI scans were carried out after second DEB TACE with the median period of 35 days. In 5% (n = 6) of patients, post-treatment response was assessed using MRI scan carried out after third DEB TACE (median of 27 days). Table 3 shows the overall and target objective response rates, and their corresponding median survival recorded for each of the four radiological criteria. Comparing RECIST 1.1 and WHO with mRECIST and EASL, there was a marked difference in response rates as shown in Table 3 . Table 4 represents Cox regression analysis and HR according to WHO, RECIST, mRECIST, and EASL guidelines. Generally, assumed order in increasing survival and decreasing hazard risk among the four categories should be CR > PR > SD > PD. The response according to the WHO and RECIST guideline failed to reflect Table 5 represents a univariate Kaplan-Meier survival analysis of target and overall responders and non-responders (SD and PD) according to WHO, RECIST, mRECIST, and EASL guidelines. There were significant survival difference among the responders and non-responders according to mRECIST and EASL guidelines (P ≤ 0.0001). The responders according to WHO and RECIST1.1 criteria showed lower survival than non-responders. Figure 1 demonstrates survival curves generated by Kaplan-Meier analysis among responder and non-responders of target and overall response according to WHO, RECIST, mRECIST, and EASL guidelines.
Multivariate analysis with the Cox regression method was used to assess the association between each method and overall survival ( Table 5 ). The difference between responders and nonresponders of overall objective response reached statistical significance for mRECIST, but not for EASL (P = 0.013 versus 0.064). The EASL non-responders had 207% increased risk when compared with responders, while mRECIST responders had 250% increased risk when compared with responders. For WHO and RECIST 1.1 overall objective response, no significant difference between responders and non-responders was observed (P = 0.22 and 0.92, accordingly), and also for the WHO and RECIST1.1 overall non-responders showed decreased risk when compared with responders.
For overall and target response, the major difference of EASL and mRECIST was in between PD and SD ( Table 3 ). The reason for the discrepancy is that mRECIST only takes into account the long-axis measurement of enhancing tumor, while EASL considers the product of the two diameters of enhancing tumor (supplementary Figure S2 , available at Annals of Oncology online).
discussion
The accurate imaging evaluation of the treatment response is essential in cancer treatments, because a tumor response on imaging after therapy is widely used as surrogate of survival. It is also used as the gold standard to select experimental treatments for further study in phase III randomized trials. HCC is a highly lethal malignancy with which the patient usually presents beyond curative treatment (resection or transplantation) [4] . The available options for the majority of the patients with HCC are systemic and LRTs (ablation and chemoembolization). The local therapies such as embolization Median survival could not be obtained because of small sample size, and >50% of the patients were alive and censored at the end of study period.
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for HCC, causes acute necrosis with no immediate change in tumor size. The WHO and RECIST criteria disregard the extent of necrosis, which is the objective of all LRTs. Therefore, an EASL and mRECIST criteria were developed to consider the amount of tumor necrosis induced by the treatment for the imaging assessment of post-treatment tumor response [20] [21] [22] . Several studies have shown survival correlation with these different radiological response guidelines [18, 19, 26] . However, to our knowledge, the WHO, RECIST1.1, mRECIST, and EASL criteria have neither been compared nor analyzed with regard to survival, using a single modality and measured at a single time point in a large series of patients with unresectable HCC treated with DEB TACE. In this study, we compared these four response criteria by dynamic MRI studies in patients with HCC after DEB TACE with the use of univariate and multivariate analyses. For the first time, we have shown that the mRECIST method demonstrates higher survival correlation when compared with EASL, WHO, and RECIST criteria in patients with unresectable HCC treated with DEB TACE. Previously, Forner et al. [19] reported overall response rates of 21.8% for RECIST and 81.8% for EASL in 55 patients undergoing a variety of locoregional treatments for HCC (radiofrequency ablation, percutaneous ethanol injection or TACE). The authors concluded RECIST missed all CRs and underestimated treatment efficacy, although no correlation was made with survival [19] . Similarly, discrepant findings were reported by Keppke et al. [27] for 42 HCC patients treated with radioembolization (RECIST 23%, WHO 26%, and necrotic area 59%). Riaz et al. [28] compared WHO, RECIST, and EASL responses in the 'primary index lesion' for a mixed cohort of HCC patients treated with TACE or radioembolization. This study also confirmed a lower response rate for conventional criteria, WHO (42.4%) and RECIST (41.2%), when compared with EASL (70.2%). More recently, Shim et al. [29] and Gillmore et al. [18] were the first to compare the mRECIST with other response criteria (EASL and RECIST) with the use of mixed modalities (CT and MRI) in a mixed cohort of HCC patients treated with bland embolization or conventional TACE in the Gillmore et al. study and only in conventional TACE in the Shim et al. study. The results of both of these studies demonstrated that EASL and mRECIST response evaluation methods helped in predicting long-term survival than RECIST [18, 29] . The overall and target response rates in the Gillmore et al. [18] study were 58%, 57% and 74%, 73% for EASL and mRECIST, respectively. In our study, the response rates were lower as we assessed the imaging response on early post-DEB TACE MRI scan with a median period of 33.5 days between the initial DEB TACE and post-treatment MRI scans, which were 64 days in the Gillmore et al. study. Additionally, in 61.7% of patients, post-treatment response was original articles Annals of Oncology assessed using MRI scans carried out after first DEB TACE in our study, and this information was lacking in the Gillmore et al. study. In this study, RECIST and WHO criteria missed all CRs and showed poor correlation with survival. We assessed target and overall response and found that the response rates were higher for both EASL (48.3% and 39.2%) and mRECIST (61.3% and 52.5%) than WHO and RECIST (5% and 4.1%, 10.8% and 10.8%). Between the EASL and mRECIST, the survival correlation was higher and most significant for mRECIST. Previously, no studies have made comparison of all four criteria with single MR modality in patients with HCC treated with DEB TACE. One important finding from our analysis is that mRECIST was an independent predictor of survival and was associated with reduction in the risk of death on both overall and target response survival evaluations. When compare with EASL response criteria, mRECIST criteria were easier to measure because the mRECIST method only considers the longest diameter of the viable tumor, while EASL method includes cross product of the viable tumor ( Table 1) .
The limitation of this study is the lack of cytopathologic confirmation of the radiologic responses. However, several recent 
studies have demonstrated that dynamic contrast-enhanced MRI study enables an accurate assessment of the necrosis of HCC after TACE with the best accuracy observed at the arterial phase [30, 31] . So, the contrast-enhanced MRI helps in accurate measurement of tumor necrosis and to measure radiologic response by different imaging criteria [13] [14] [15] [16] [20] [21] [22] .
In conclusion, EASL and mRECIST responses measured on MRI at a single early time point after DEB TACE predicted survival. The results from this study indicated a higher survival correlation of mRECIST method when compared with EASL, WHO, and RECIST response methods on MRI carried out after early DEB TACE in patients with unresectable HCC. WHO and RECIST showed poor correlation with survival. 
